| Date Filed | Type | Description |
| 08/09/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
4
| Lemerond Nicole (Director) has filed a Form 4 on MEDICINOVA INC|
Txns:
| Granted 18,333 options to buy
@ $2.47, valued at
$45.3k
|
|
| 08/08/2023 |
3
| Lemerond Nicole (Director) has filed a Form 3 on MEDICINOVA INC |
| 08/07/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/15/2023 |
4
| Nagao Hideki (Director) has filed a Form 4 on MEDICINOVA INC|
Txns:
| Granted 20,000 options to buy
@ $2.23, valued at
$44.6k
|
|
| 06/15/2023 |
4
| BEAVER CAROLYN (Director) has filed a Form 4 on MEDICINOVA INC|
Txns:
| Granted 20,000 options to buy
@ $2.23, valued at
$44.6k
|
|
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/26/2023 |
8-K
| Quarterly results |
| 04/26/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/26/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/26/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/28/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
| 01/25/2023 |
4
| IWAKI YUICHI (President and CEO) has filed a Form 4 on MEDICINOVA INC|
Txns:
| Granted 235,125 options to buy
@ $2.25, valued at
$529k
|
|
| 01/25/2023 |
4
| OBrien Geoffrey (Vice President) has filed a Form 4 on MEDICINOVA INC|
Txns:
| Granted 76,950 options to buy
@ $2.25, valued at
$173.1k
|
|
| 01/25/2023 |
4
| Matsuda Kazuko (Chief Medical Officer) has filed a Form 4 on MEDICINOVA INC|
Txns:
| Granted 149,625 options to buy
@ $2.25, valued at
$336.7k
|
|
| 11/30/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/23/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/21/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/10/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 09/30/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 09/07/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/26/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 08/11/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 07/12/2022 |
SC 13D/A
| 3D Investment Partners Pte. Ltd. reports a 11.2% stake in MEDICINOVA, INC. |
| 06/27/2022 |
3
| Kruger Jason J (CFO) has filed a Form 3 on MEDICINOVA INC |
| 06/21/2022 |
8-K
| Quarterly results |
| 06/17/2022 |
4
| Nagao Hideki (Director) has filed a Form 4 on MEDICINOVA INC|
Txns:
| Granted 20,000 options to buy
@ $2.51, valued at
$50.2k
|
|
| 06/17/2022 |
4
| BEAVER CAROLYN (Director) has filed a Form 4 on MEDICINOVA INC|
Txns:
| Granted 20,000 options to buy
@ $2.51, valued at
$50.2k
|
|
| 06/15/2022 |
8-K
| Quarterly results |
| 05/13/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 05/12/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 04/26/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/26/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 02/16/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
|